Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 16,141 shares at $26.93 ($435K) on 2026-10-01, disclosed to the SEC on 2026-10-02.
Scheduled sale ($435k) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |
| MAZE | SELL | 2026-07-02 | $437K | — | Filing → |